Clinical Trial Update: Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia [NA]

View source ↗

Summary

This clinical trial is evaluating first-line zanubrutinib in combination with bendamustine and rituximab for Waldenström's macroglobulinemia; the trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Waldenström's Macroglobulinemia (WM) | NA | Status: NOT_YET_RECRUITING